A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease. * Measurable disease by RECIST guidelines. * Tumor (primary or metastatic) must be HER2 negative. * Adequate organ and hematologic function. Exclusion: * Taxane treatment within 12 months prior to registration. * Prior chemotherapy for locally recurrent or metastatic breast cancer (prior endocrine therapy is permitted). * Prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic chemoembolization on all sites of measurable disease. * Current or prior history of central nervous system metastases. * Peripheral neuropathy ≥ grade 2 (CTCAE v3.0) at registration. * History of arterial or venous thrombosis within 1 year prior to registration. * History of bleeding diathesis or bleeding within 14 days of registration. * Uncontrolled hypertension (systolic \>145 mmHg; diastolic \>85 mmHg). * Clinically significant cardiac disease within 12 months of registration. * Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive. * Prior treatment with VEGFr targeted therapies.